Catalyst Pharmaceuticals - CPRX Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Catalyst Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CPRX shares.
View CPRX analyst ratings or view top-rated stocks.

4 brokers have issued 12 month target prices for Catalyst Pharmaceuticals' shares. Their CPRX share price forecasts range from $15.50 to $18.00. On average, they expect the company's stock price to reach $17.13 in the next year. This suggests a possible upside of 1.9% from the stock's current price.
View analysts price targets for CPRX or view top-rated stocks among Wall Street analysts.

Catalyst Pharmaceuticals' stock was trading at $6.77 at the beginning of 2022. Since then, CPRX stock has increased by 148.2% and is now trading at $16.80.
View the best growth stocks for 2022 here.

Catalyst Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 6,670,000 shares, a decline of 17.2% from the October 31st total of 8,060,000 shares. Based on an average trading volume of 3,260,000 shares, the short-interest ratio is presently 2.0 days. Currently, 6.8% of the company's stock are sold short.
View Catalyst Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our CPRX earnings forecast.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.10. The biopharmaceutical company earned $35.95 million during the quarter, compared to analyst estimates of $34.47 million. Catalyst Pharmaceuticals had a net margin of 34.90% and a trailing twelve-month return on equity of 28.53%. During the same period in the prior year, the business posted $0.11 EPS.

Catalyst Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$210.00 million, compared to the consensus revenue estimate of $205.03 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalyst Pharmaceuticals investors own include Novavax (NVAX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Micron Technology (MU), Verastem (VSTM), Exelixis (EXEL), Rigel Pharmaceuticals (RIGL) and TherapeuticsMD (TXMD).

Catalyst Pharmaceuticals trades on the NASDAQ under the ticker symbol "CPRX."

Catalyst Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.67%), State Street Corp (7.26%), Vanguard Group Inc. (5.90%), LSV Asset Management (3.30%), Renaissance Technologies LLC (2.14%) and Dimensional Fund Advisors LP (2.08%). Insiders that own company stock include Alicia Grande, Charles B O'keeffe, David S Tierney, Donald A Denkhaus, Gary Ingenito, Patrick J Mcenany, Philip H Coelho, Preethi Sundaram and Steve Miller.
View institutional ownership trends.

Shares of CPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CPRX stock can currently be purchased for approximately $16.80.

Catalyst Pharmaceuticals (NASDAQ:CPRX) has a market capitalization of $1.75 billion and generates $140.83 million in revenue each year. The biopharmaceutical company earns $39.48 million in net income (profit) each year or $0.61 on an earnings per share basis.

Catalyst Pharmaceuticals' mailing address is 355 ALHAMBRA CIRCLE SUITE 1250, CORAL GABLES FL, 33134. The official website for the company is www.catalystpharma.com. The biopharmaceutical company can be reached via phone at (305) 420-3200, via email at bkorb@troutgroup.com, or via fax at 305-529-0933.